Form 4 for NGNE Neurogene Inc.
Accepted 2025-03-28 00:00:00 ET · period of report 2025-03-26 · accession 0001404644-25-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-28 | 2025-03-26 | NGNE | McMinn Rachel | CEO, Dir | A - Grant | $0.00 | +23.9K | 1.27M | +2% | $0 |
| D | 2025-03-28 | 2025-03-26 | NGNE | McMinn Rachel | CEO, Dir | A - Grant | $0.00 | +143.5K | 143.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-26 | A | A | 23,900 | $0.00 | 1,274,259 | D | — | — | (F1) Consist of 23,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. |
| 2 | Derivative | Employee Stock Option (Right to buy) | 2025-03-26 | A | A | 143,500 | $0.00 | 143,500 | D | $16.14 · 2025-03-26 to — | 143,500 Common Stock | (F2) This option represents the right to purchase 143,500 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. |